ISRCTN25916618 https://doi.org/10.1186/ISRCTN25916618

HMR code: 25-018

Submission date 24/06/2026	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 29/06/2026	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 23/07/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Public, Scientific

Contact name
None Global Regulatory

Contact details
Silence Therapeutics Plc., 12 Hammersmith Grove
London
United Kingdom
W6 7AP
N/A
global-regulatory@silence-therapeutics.com

Type(s)
Principal investigator

Contact name
Dr Takahiro Yamamoto

ORCID ID
https://orcid.org/0000-0001-9121-0836

Contact details
Hammersmith Medicines Research (HMR), Cumberland Avenue, Park Royal
London
United Kingdom
NW10 7EW

+44 (0)20 8961 4130
rec@hmrlondon.com

Additional identifiers

Integrated Research Application System (IRAS)
1013877

CRO trial code
25-018

Study information

Scientific Title
HMR code: 25-018 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 18/06/2026, London – Harrow Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8345; harrow.rec@hra.nhs.uk), ref: 26/LO/0232

Primary study design
Interventional

Allocation
Non-randomized controlled trial

Masking
Open (masking not used)

Control
Active

Assignment
Parallel

Purpose
Phase I trial in healthy participants

Study type(s)

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Completion date
16/12/2026

Eligibility

Key inclusion criteria
Healthy human volunteers

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
18 Years

Upper age limit
65 Years

Sex
All

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
02/07/2026

Date of final enrolment
22/07/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Hammersmith Medicines Research (HMR)
Cumberland Avenue, Park Royal
London
England
NW10 7EW

Sponsor information

Organisation
Silence Therapeutics (United Kingdom)

ROR
https://ror.org/03p3e4237

Funder(s)

Funder type

Funder Name
Silence Therapeutics

Alternative Name(s)
Silence Therapeutics plc

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available